Table 6 The lncRNA-mediated PD-specific miRNAs associated the PD-specific mRNAs identified in our study regulatory network

Blood

hsa-miR-204-3p

LINC00999

HSPA6

hsa-miR-17-3p

RP3-323A16.1, XIST

SRPK2

Activation:CCND1,E2F1,MYC, MYCN, NKX2–5, TLX1, TLX3, TNF, ERS1, STAT5;

Repression: NFKB1, SPI1; Neutral: MAPK14

hsa-miR-181a-5p

AC000403.4, CASC7, CTB-89H12.4, KCNQ1OT1, LINC00506, N4BP2L2-IT2, RP11-10E18.7, RP11-1134I14.8, RP11-147 L13.14, RP11-314B1.2, RP11-361F15.2, RP11-707A18.1, RP1-309I22.2, ZNF883, ZNRD1-AS1

SRPK2

Neutral: TP63

hsa-miR-181b-5p

CASC7, CTB-89H12.4, KCNQ1OT1, RP11-1134I14.8, XIST

SRPK2

hsa-miR-181c-5p

CTB-89H12.4, KCNIP4-IT1, KCNQ1OT1, RP11-1134I14.8

SRPK2

Activation: AKT1

hsa-miR-181d

SRPK2

hsa-miR-19a-3p

FAM201A, H19, KCNA3, KCNQ1OT1, LINC00094, RP11-337C18.8, RP11-523G9.3, SNHG14

SRPK2

Activation: E2F1, MYC, MYCN, NKX2–5, TLX1, TLX3, ERS1, STAT5; Repression:SPI1; Neutral:PTEN, MAPK14

hsa-miR-19b-3p

CASC7, FAM201A, H19, KCNA3, KCNQ1OT1, LINC00094, RP11-337C18.8, RP11-523G9.3, SNHG14

SRPK2

Activation: E2F1, MYC, MYCN, NKX2–5, TLX1, TLX3, ERS1;

Neutral: MAPK14

hsa-miR-199a-3p

CTB-89H12.4, ERVK3–1, XIST

NOL7

Neutral: TWIST1

Substantia nigra

hsa-miR-93-3p

AC012065.7,KCNQ1OT1, LINC00342

SNCA

Repression: MYC;

Neutral: E2F1

hsa-miR-153

SNCA

hsa-miR-23b-3p

CASC7,CTC-459F4.3, KCNQ1OT1, RP11-215G15.5, SNHG14, TOB1-AS1, XIST, ZNRD1-AS1

SNCA

Repression: MYC;

Neutral: ESR2

hsa-miR-34a-5p

AC005154.6, H19, KCNQ1OT1, LINC00674, MIR4697HG, NEAT1, RP11-314B1.2, RP11-582E3.6, RP4-630A11.3, THUMPD3-AS1, TTTY15, TUG1

SNCA

Activation: HMGA1, AP-1;

Repression: MYC, NFKB1, YY1, IL-4, PDGF-B, TGFB1;

Neutral: CEBPA

hsa-miR-7-5p

CTB-89H12.4, KCNQ1OT1, RP11-273G15.2, RP11-314B1.2, RP11-793H13.8, SNHG14, TSNAX-DISC1, TUG1

SNCA

Activation: NFKB1, IL1B, TLR2, TLR4, TLR7,

TLR8, TNF, MYC, NFKB1;

Repression: TLX